益肝化湿饮对乙肝肝纤维化患者T淋巴细胞亚群的影响

Influence of Yigan Huashi Decoction on T lymphocyte subsets in patients with hepatitis B liver fibrosis

目的探讨益肝化湿饮联合恩替卡韦对乙肝肝纤维化患者T淋巴细胞亚群的影响。方法将118例乙肝肝纤维化患者随机分为对照组(60例)和治疗组(58例)。对照组采用恩替卡韦等常规治疗,治疗组在常规治疗基础上加用益肝化湿饮治疗。24周为1个治疗周期,观察两组患者的T淋巴细胞亚群、中医证候、肝功能、肝纤维化指标的变化。结果经过24周治疗,治疗组的有效率为87.93%,对照组为71.67%,治疗组优于对照组,差异有统计学意义(P<0.05);两组患者的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较治疗前升高,治疗组CD4^(+)、CD4^(+)/CD8^(+)的升高优于对照组,差异有统计学意义(P<0.05);两组患者的肝纤维化指标均较治疗前降低(均P<0.05),治疗组显著低于对照组,差异有统计学意义(P<0.05)。结论益肝化湿饮可延缓乙肝肝纤维化的进展,其作用机制可能与调控T淋巴细胞亚群有关。

Objective To explore the effect of Yigan Huashi Decoction combined with entecavir on T lymphocyte subsets in patients with hepatitis B liver fibrosis.Methods One hundred and eighteen patients with hepatitis B liver fibrosis were randomly divided into control group(60 cases) and treatment group(58 cases). The control group was given routine treatment and the treatment group received Yigan Huashi Decoction on the basis of the control group. The course of treatment was 24 weeks. The T lymphocyte subsets, symptom scores, liver function and liver fibrosis indexes were compared for both groups, before and after treatment.Results After 24 weeks'treatment, the total effective rate was 87.93% in the treatment group, which was better than that 71.67% in the control group. The levels of CD3^(+), CD4^(+), CD4^(+)/CD8^(+) were obviously increased compared with treatment before and the CD4^(+), CD4^(+)/CD8^(+) of the treatment group was higher than the control group(P < 0.05). The liver fibrosis indexes were decreased compared with treatment before. The treatment group was significantly lower than that in the control group(P < 0.05).Conclusion Yigan Huashi Decoction can delay the progression of hepatic fibrosis. The mechanism may be related to regulating the level of T lymphocyte subsets.